Biomea Fusion (BMEA)
(Delayed Data from NSDQ)
$12.24 USD
-0.54 (-4.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $12.23 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMEA 12.24 -0.54(-4.23%)
Will BMEA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMEA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMEA
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
BMEA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
Other News for BMEA
Biomea Fusion GAAP EPS of -$1.09 misses by $0.02
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
Analysts’ Top Healthcare Picks: Cigna (CI), Biomea Fusion (BMEA)
Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)